| 000 | 01785 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517144531.0 | ||
| 264 | 0 | _c20170817 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2016-11-750158 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarzon, Ramiro | |
| 245 | 0 | 0 |
_aA phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. _h[electronic resource] |
| 260 |
_bBlood _c06 2017 |
||
| 300 |
_a3165-3174 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlast Crisis _xblood |
| 650 | 0 | 4 |
_aBone Marrow Cells _xmetabolism |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazines _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTriazoles _xadministration & dosage |
| 700 | 1 | _aSavona, Michael | |
| 700 | 1 | _aBaz, Rachid | |
| 700 | 1 | _aAndreeff, Michael | |
| 700 | 1 | _aGabrail, Nashat | |
| 700 | 1 | _aGutierrez, Martin | |
| 700 | 1 | _aSavoie, Lynn | |
| 700 | 1 | _aMau-Sorensen, Paul Morten | |
| 700 | 1 | _aWagner-Johnston, Nina | |
| 700 | 1 | _aYee, Karen | |
| 700 | 1 | _aUnger, Thaddeus J | |
| 700 | 1 | _aSaint-Martin, Jean-Richard | |
| 700 | 1 | _aCarlson, Robert | |
| 700 | 1 | _aRashal, Tami | |
| 700 | 1 | _aKashyap, Trinayan | |
| 700 | 1 | _aKlebanov, Boris | |
| 700 | 1 | _aShacham, Sharon | |
| 700 | 1 | _aKauffman, Michael | |
| 700 | 1 | _aStone, Richard | |
| 773 | 0 |
_tBlood _gvol. 129 _gno. 24 _gp. 3165-3174 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2016-11-750158 _zAvailable from publisher's website |
| 999 |
_c27009804 _d27009804 |
||